Martelletti P - Search Results

1

Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention.

Pellesi L, Ashina M, Martelletti P. Pellesi L, et al. Among authors: martelletti p. Expert Opin Emerg Drugs. 2024 Mar;29(1):57-64. doi: 10.1080/14728214.2024.2317778. Epub 2024 Feb 12. Expert Opin Emerg Drugs. 2024. PMID: 38337150 Review.

2

Emerging treatment for chronic migraine and refractory chronic migraine.

Lionetto L, Negro A, Palmisani S, Gentile G, Del Fiore MR, Mercieri M, Simmaco M, Smith T, Al-Kaisy A, Arcioni R, Martelletti P. Lionetto L, et al. Among authors: martelletti p. Expert Opin Emerg Drugs. 2012 Sep;17(3):393-406. doi: 10.1517/14728214.2012.709846. Epub 2012 Aug 3. Expert Opin Emerg Drugs. 2012. PMID: 22862686 Review.

3

The therapeutic potential of novel anti-migraine acute therapies.

Sabato D, Lionetto L, Martelletti P. Sabato D, et al. Among authors: martelletti p. Expert Opin Investig Drugs. 2015 Feb;24(2):141-4. doi: 10.1517/13543784.2015.983223. Epub 2014 Nov 13. Expert Opin Investig Drugs. 2015. PMID: 25391253

4

Emerging drugs for migraine treatment.

Giamberardino MA, Martelletti P. Giamberardino MA, et al. Among authors: martelletti p. Expert Opin Emerg Drugs. 2015 Mar;20(1):137-47. doi: 10.1517/14728214.2015.999040. Epub 2014 Dec 30. Expert Opin Emerg Drugs. 2015. PMID: 25547922 Review.

5

European Headache Federation consensus on technical investigation for primary headache disorders.

Mitsikostas DD, Ashina M, Craven A, Diener HC, Goadsby PJ, Ferrari MD, Lampl C, Paemeleire K, Pascual J, Siva A, Olesen J, Osipova V, Martelletti P; EHF committee. Mitsikostas DD, et al. Among authors: martelletti p. J Headache Pain. 2015;17:5. doi: 10.1186/s10194-016-0596-y. Epub 2016 Feb 9. J Headache Pain. 2015. PMID: 26857820 Free PMC article.

6

Lasmiditan for the treatment of migraine.

Capi M, de Andrés F, Lionetto L, Gentile G, Cipolla F, Negro A, Borro M, Martelletti P, Curto M. Capi M, et al. Among authors: martelletti p. Expert Opin Investig Drugs. 2017 Feb;26(2):227-234. doi: 10.1080/13543784.2017.1280457. Expert Opin Investig Drugs. 2017. PMID: 28076702 Review.

7

Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy.

Guerzoni S, Pellesi L, Baraldi C, Cainazzo MM, Negro A, Martelletti P, Pini LA. Guerzoni S, et al. Among authors: martelletti p. Front Neurol. 2017 Nov 3;8:586. doi: 10.3389/fneur.2017.00586. eCollection 2017. Front Neurol. 2017. PMID: 29163347 Free PMC article.

8

Pituitary adenylate-cyclase-activating polypeptide (PACAP): another novel target for treatment of primary headaches?

Ashina M, Martelletti P. Ashina M, et al. Among authors: martelletti p. J Headache Pain. 2018 May 8;19(1):33. doi: 10.1186/s10194-018-0860-4. J Headache Pain. 2018. PMID: 29740710 Free PMC article. No abstract available.

9

Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation.

Bendtsen L, Sacco S, Ashina M, Mitsikostas D, Ahmed F, Pozo-Rosich P, Martelletti P. Bendtsen L, et al. Among authors: martelletti p. J Headache Pain. 2018 Sep 26;19(1):91. doi: 10.1186/s10194-018-0921-8. J Headache Pain. 2018. PMID: 30259200 Free PMC article.

10

Emerging drugs for migraine treatment: an update.

Lambru G, Andreou AP, Guglielmetti M, Martelletti P. Lambru G, et al. Among authors: martelletti p. Expert Opin Emerg Drugs. 2018 Dec;23(4):301-318. doi: 10.1080/14728214.2018.1552939. Epub 2018 Nov 30. Expert Opin Emerg Drugs. 2018. PMID: 30484333 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

385 results

Search Page